Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort.
CONCLUSION: Biosimilar and original etanercept showed similar efficacy and safety after the first 6 months of treatment in RA patients from a national registry, which brings further evidence for biosimilarity in unselected patients in real-world setting.
PMID: 31668853 [PubMed - as supplied by publisher]
Source: Biologicals : Journal of the International Association of Biological Standardization - Category: Biotechnology Authors: Codreanu C, Popescu CC, Mogoșan C, Enache L, Daia S, Ionescu R, Opriș-Belinski D Tags: Biologicals Source Type: research
More News: Anaphylactic Shock | Arthritis | Biotechnology | Enbrel | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | Romania Health | Study | Vasculitis